CCR5 and infection: For all the M-tropic and R5 T cell-tropic pseudotyped viruses, Maraviroc decreased infection up to 100-fold in a dose-dependent manner, whereas AMD3100 did not alter infection, consistent with CCR5 coreceptor usage (data not shown for the 4059 M- and T-tropic pseudotyped viruses).